Characteristics of hematopoietic stem cell transplantation patients
| Patient characteristics . | Nonmyeloablative transplant (n = 56) . | Myeloablative transplant (n = 112) . |
|---|---|---|
| Sex (female/male), % | 25/75 | 37/63 |
| Disease, % | ||
| ALL | 2 | 15 |
| ANL | 14 | 22 |
| CLL | 14 | 2 |
| CML | 5 | 17 |
| HD | 11 | 0 |
| MDS | 11 | 25 |
| MM | 23 | 5 |
| NHL | 18 | 13 |
| Other | 2* | 1† |
| Diagnosis group, % | ||
| Good | 32 | 56 |
| Poor | 68 | 44 |
| Age at transplantation | ||
| Median age, % | 54 | 46 |
| Younger than 20 y, % | 2 | 4 |
| Age 20-40 y, % | 9 | 19 |
| Older than 40 y, % | 89 | 78 |
| CMV risk group, % | ||
| Low | 21 | 21 |
| Intermediate | 18 | 18 |
| High | 61 | 61 |
| Donor, % | ||
| HLA-matched related donor | 93 | 93 |
| HLA-matched unrelated donor | 7 | 7 |
| Median donor age, y | 50 | 43 |
| Stem cell source, % | ||
| BM | 4 | 4 |
| PBSCs | 96 | 96 |
| Conditioning, % | ||
| TBI (2 Gy) | 67 | |
| TBI (2 Gy) + fludarabine | 33 | |
| Busulfan/cyclophosphamide | 39 | |
| Cyclophosphamide/TBI (above 10 Gy) | 38 | |
| Busulfan/TBI (above 10 Gy) | 13 | |
| Other | 9 | |
| GVHD prophylaxis, % | ||
| CSP + MMF | 100 | 4 |
| CSP + methotrexate | 91 | |
| CSP | 3 | |
| Other | 3 |
| Patient characteristics . | Nonmyeloablative transplant (n = 56) . | Myeloablative transplant (n = 112) . |
|---|---|---|
| Sex (female/male), % | 25/75 | 37/63 |
| Disease, % | ||
| ALL | 2 | 15 |
| ANL | 14 | 22 |
| CLL | 14 | 2 |
| CML | 5 | 17 |
| HD | 11 | 0 |
| MDS | 11 | 25 |
| MM | 23 | 5 |
| NHL | 18 | 13 |
| Other | 2* | 1† |
| Diagnosis group, % | ||
| Good | 32 | 56 |
| Poor | 68 | 44 |
| Age at transplantation | ||
| Median age, % | 54 | 46 |
| Younger than 20 y, % | 2 | 4 |
| Age 20-40 y, % | 9 | 19 |
| Older than 40 y, % | 89 | 78 |
| CMV risk group, % | ||
| Low | 21 | 21 |
| Intermediate | 18 | 18 |
| High | 61 | 61 |
| Donor, % | ||
| HLA-matched related donor | 93 | 93 |
| HLA-matched unrelated donor | 7 | 7 |
| Median donor age, y | 50 | 43 |
| Stem cell source, % | ||
| BM | 4 | 4 |
| PBSCs | 96 | 96 |
| Conditioning, % | ||
| TBI (2 Gy) | 67 | |
| TBI (2 Gy) + fludarabine | 33 | |
| Busulfan/cyclophosphamide | 39 | |
| Cyclophosphamide/TBI (above 10 Gy) | 38 | |
| Busulfan/TBI (above 10 Gy) | 13 | |
| Other | 9 | |
| GVHD prophylaxis, % | ||
| CSP + MMF | 100 | 4 |
| CSP + methotrexate | 91 | |
| CSP | 3 | |
| Other | 3 |
ALL indicates acute lymphocytic leukemia; ANL, acute nonlymphocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HD, Hodgkin disease; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; CMV, cytomegalovirus; BM, bone marrow; PBSCs, peripheral blood stem cells; TBI, total body irradiation; GVHD, graft-versus-host disease; CSP, cyclosporine; and MMF, mycophenolate mofetil.
Renal cell carcinoma.
Aplastic anemia.